T-cell lymphoma


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

T-cell lymphoma

A malignant proliferation of T cells arising in the skin, diagnosed by detecting rearrangement of the T-cell receptor's β chain; TCLs are often 'driven' by EBV and other viral infections; 90% of all Pts with TCL have extracutaneous involvement when diagnosed. See Mycosis fungoides.
T-cell lymphomas
Small lymphocytic (well-differentiated lymphocyte-like) lymphoma–13%
Convoluted cell lymphoma or poorly-differentiated lymphocytic lymphoma–52%
Immunoblastic sarcoma or 'histiocytic' lymphoma–19%
Mycosis fungoides/Sézary syndrome–11%
Lymphoepithelial cell (Lennert's) lymphoma–5%
Cutaneous T-cell lymphoma
HTLV (I, II)–induced lymphoma

T-cell lymphoma

See MYCOSIS FUNGOIDES.
References in periodicals archive ?
Gemmill, "Cutaneous T-cell lymphoma," Seminars in Oncology Nursing, vol.
Type II enteropathy-associated T-cell lymphoma is a subset of EATL which does not appear to be associated with celiac disease and therefore has a broader geographic distribution.
* Coverage of the Cutaneous T-Cell Lymphoma pipeline on the basis of route of administration and molecule type.
The 200 cases of non-Hodgkin's lymphoma included 118 T-cell lymphomas, 30 B-cell lymphomas, and 52 indeterminate types.
Many aggressive B-cell NHL seen in HIV patients, especially those with plasmacytic differentiation, often lack CD20 and exhibit aberrant T-cell antigen expression [72], These lymphomas may falsely lead to an impression of T-cell lymphoma, and could thereby skew the published data reported.
Approximately 8 years after the second sample was taken, the patient was again diagnosed and found to have angiocentric T-cell lymphoma. The CE GeneScan profiles (Fig.
Gasparro of the Yale University School of Medicine is seeking cell-surface targets for psoralen -- a treatment for psoriasis and cutaneous T-cell lymphoma -- to help explain the drug's apparent ability to stimulate an immune response against abnormally dividing skin cells.
The data demonstrated that frontline treatment with ADCETRIS (brentuximab vedotin) in combination with CHP (cyclophosphamide, doxorubicin, prednisone) is effective in extending progression-free survival (PFS) and overall survival (OS) with a safety profile comparable to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), a current standard of care in patients with CD30-expressing peripheral T-cell lymphomas (PTCL).
The US Food and Drug Administration (FDA) has received a supplemental Biologics License Application from United States-based Seattle Genetics, seeking approval for its Adcetris (brentuximab vedotin) in combination with chemotherapy intended for the frontline treatment of CD30-expressing peripheral T-cell lymphoma, it was reported yesterday.
MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA
Peripheral T-cell lymphoma (PTCL) defines a group of rare non-Hodgkin lymphomas (NHL) characterized by an aggressive clinical course and dismal prognosis.
-- Psoriasis of all severities was linked to a 3.5-fold increase in risk of cutaneous T-cell lymphoma, and severe psoriasis upped the associated risk of Hodgkin lymphoma by about 2.5 times, in a large, longitudinal, population-based cohort study.